Table 1

Baseline Characteristics of the Patients, According to the Study Group

Ranolazine (n = 462)Placebo (n = 465)
Age, yrs63.2 ± 8.564.2 ± 8.4
Men283 (61.3%)286 (61.5%)
White456 (98.7%)462 (99.4%)
Hypertension438 (95.0%)445 (95.9%)
Dyslipidemia350 (79.4%)355 (80.3%)
Current smoking71 (15.4%)77 (16.6%)
Prior myocardial infarction346 (75.4%)336 (72.7%)
Prior angioplasty197 (42.7%)180 (38.8%)
Prior bypass graft surgery84 (18.2%)88 (18.9%)
Duration of diabetes, yrs7.2 ± 6.77.7 ± 7.0
HbA1c, %7.3 ± 1.57.3 ± 1.5
Antidiabetic medication431 (93.3%)431 (92.7%)
Insulin81 (17.5%)96 (20.6%)
Antianginal medications
 On 1259 (56.1%)259 (55.7%)
 On 2203 (43.9%)206 (44.3%)
 Beta-blockers418 (90.5%)418 (89.9%)
 Calcium-channel blockers124 (26.8%)143 (30.8%)
 Long-acting nitrates161 (34.8%)151 (32.5%)
Statins381 (82.5%)383 (82.4%)
Antiplatelet agents415 (89.8%)402 (86.5%)
ACE-I/ARBs407 (88.1%)407 (87.5%)
Baseline heart rate (beats/min)69.0 ± 8.070.0 ± 9.8
Baseline systolic blood pressure (mm Hg)131.0 ± 11.0131.0 ± 11.3
Baseline diastolic blood pressure (mm Hg)79.0 ± 7.779.0 ± 7.8

Values are n mean ± SD or (%).

ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker.